n
raphael
shulman
md
clinic
hematolog
branch
nation
institut
arthriti
metabol
diseas
nation
institut
health
bethesda
maryland
request
reprint
address
dr
n
raphael
shulman
identif
antigen
intim
relat
caus
agent
viral
hepat
given
impetu
hepat
research
blumberg
associ
found
antigen
incident
work
precipitin
iipoprotein
allotyp
precipitin
serum
patient
hemophilia
receiv
multipl
transfus
antigen
happen
serum
australian
aborigin
precipitin
line
form
ouchterloni
doubl
diffus
differ
specif
known
iipoprotein
antigen
call
australia
antigen
au
antigen
consid
inherit
recess
trait
base
statist
analys
occurr
larg
tropic
popul
relationship
gradual
recogn
next
four
year
australia
antigen
leukemia
syndrom
lepromat
leprosi
hepat
possibl
consid
au
trait
might
associ
suscept
virus
okochi
murakami
confirm
associ
australia
antigen
hepat
demonstr
appear
antigen
incub
period
acut
phase
classic
posttransfus
viral
hepat
princ
report
similar
observ
patient
serum
hepat
call
antigen
sh
examin
immun
precipit
au
electron
microscopi
show
aggreg
particl
shortli
thereaft
close
relationship
australia
antigen
occurr
viral
hepat
presenc
viruslik
particl
antigen
serum
confirm
although
sever
differ
name
appli
antigen
singl
well
document
specif
exist
mani
worker
adopt
gener
term
hepatitisassoci
antigen
haa
rather
genet
nomenclatur
au
blumberg
et
al
circumscript
sh
antigen
princ
review
summar
inform
physic
chemic
characterist
hepatitisassoci
antigen
haa
clinic
circumst
haa
antihaa
occur
associ
haa
transmiss
hepat
relationship
antihaa
immun
suitabl
variou
technic
measur
haa
antihaa
first
peak
serum
filtrat
sephadex
gel
travel
globulin
gel
electrophoresi
appear
contain
small
amount
lipid
basi
weak
reaction
sudan
black
differ
lipoprotein
immunoreact
densiti
haa
dens
iipoprotein
fraction
sediment
potassium
oromid
specif
graviti
lighter
serum
protein
fraction
specif
graviti
antigen
consid
possibl
alter
partial
delipid
lipoprotein
viruslik
natur
reveal
electron
microscopi
precipit
haa
form
specif
antiserum
precipit
contain
conglomer
particl
approxim
diamet
elong
structur
diamet
vari
length
within
year
sever
group
investig
report
presenc
viruslik
particl
serum
posit
haa
immunolog
test
viruslik
characterist
haa
particl
aggreg
antibodi
pellet
ten
minut
g
readili
seen
neg
stain
figur
particl
modal
diamet
approxim
figur
prepar
occasion
particl
appear
central
core
figur
usual
conspicu
larg
spheric
particl
seen
figur
differ
serum
specimen
contain
vari
number
tubular
filament
form
show
period
figur
size
filament
larg
spheric
form
separ
uniform
spheric
form
differenti
rate
sediment
cesium
chlorid
gradient
organ
solvent
disrupt
tubular
form
suggest
may
consist
spheric
particl
insid
common
lipidcontain
membran
perhap
cellular
origin
ether
treatment
reduc
diamet
spheric
particl
approxim
figur
suggest
remov
outer
coat
coat
may
contain
lipid
densiti
particl
measur
cesium
chlorid
gradient
increas
approxim
treatment
approxim
treatment
organ
solvent
one
report
suggest
treatment
mild
deterg
tween
freez
thaw
may
remov
lighter
capsid
materi
increas
densiti
haa
rang
cesium
chlorid
gradient
appar
heavier
haa
could
detect
complement
fixat
electron
microscopi
investig
think
particl
appar
core
materi
inner
bodi
repres
complet
viru
infecti
virion
particl
separ
yet
numer
appar
empti
particl
determin
whether
contain
nucleotid
dane
et
al
report
particl
similar
larger
spheric
particl
shown
figur
consid
complet
viru
haaposit
specimen
three
patient
particl
probabl
aggreg
smaller
sphere
disrupt
ether
tubular
form
although
particl
appear
slightli
dens
particl
cesium
chlorid
gradient
two
size
could
separ
isopycn
band
millman
et
al
report
test
nucleotid
neg
purifi
haa
use
suffici
amount
permit
measur
ribonucl
acid
rna
per
cent
deoxyribonucl
acid
dna
per
cent
total
weight
protein
prepar
similar
attempt
investig
measur
rna
dna
purifi
haa
given
neg
result
low
densiti
haa
prepar
therefor
appear
clue
lack
nucleotid
particl
well
presenc
lipid
size
haa
particl
small
virus
picornaviru
prvoviru
arborviru
enteroviru
group
precis
classif
possibl
attribut
particl
characterist
one
group
angular
outlin
particl
appar
surfac
structur
approxim
subunit
uniform
arrang
figur
resembl
featur
defect
adenoassoci
viru
howev
picornavirus
parvovirus
adenoassoci
viru
contain
lipid
higher
buoyant
densiti
cesium
chlorid
reflect
rel
high
nucleotid
content
haa
resembl
arborvirus
size
lipid
content
densiti
resembl
enterovirus
size
stabil
howev
haa
differ
serolog
known
arborvirus
enterovirus
virus
complement
fixat
reagent
repres
serotyp
picorna
parvoand
arborvirus
fail
fix
complement
haa
antihaa
particl
stabl
morpholog
characterist
haa
antigen
immunodiffus
complement
fixat
remain
unchang
heat
one
hour
storag
room
temperatur
least
six
month
twenti
year
treatment
organ
solvent
minor
chang
shown
figur
evid
antigen
may
actual
increas
perhap
flew
site
uncov
remov
lipid
associ
antibodi
correl
observ
infect
mccollum
filtrat
experi
determin
size
serum
hepat
agent
judg
infect
human
be
show
serum
hepat
agent
could
pass
filter
averag
pore
diamet
sinc
particl
would
approxim
half
diamet
filter
pore
permit
passag
infecti
agent
probabl
size
abund
haa
particl
titer
infecti
plasma
experiment
subject
murray
estim
concentr
infecti
particl
serum
patient
serum
densiti
n
ucleotid
content
stabil
proteinlik
characterist
distribut
haa
cohn
ethanol
fraction
highli
contamin
plasma
base
chiefli
incub
period
implic
parenter
exposur
shortincub
two
six
week
call
infecti
hepat
longincub
six
twentysix
week
serum
hepat
case
parenter
exposur
consid
infecti
hepat
differenti
case
produc
jnject
materi
known
produc
shortand
longincubationperiod
hepat
respect
case
exclud
total
case
hirschman
et
al
subsequ
analyz
sensit
complement
fixat
technic
shulman
et
al
hepat
acut
phase
acut
phase
serum
concentr
haa
particl
count
electron
microscopi
similar
acut
phase
serum
usual
greater
view
dispar
biolog
evid
present
later
transmiss
hepat
materi
conrain
haa
seem
like
materi
identifi
haa
chiefli
noninfecti
empti
viru
coat
although
incomplet
viru
predomin
complet
infecti
viru
present
observ
physic
chemic
stabil
haa
consist
known
stabil
ifecti
agent
hepat
contamin
plasma
transmit
diseas
similar
treatment
heat
solvent
similar
peribd
storag
physic
chemic
attribut
haa
includ
distribut
haa
cohn
ethanol
fraction
human
plasma
summar
tabl
haa
acut
hepat
frequenc
haa
acut
hepat
initi
suggest
blumberg
cowork
australia
antigen
might
relat
infecti
agent
viral
hepat
demonstr
okochi
murakami
princ
antigen
appear
blood
patient
incub
period
serum
hepat
number
investig
report
evid
exist
hepatitisassoci
antigen
tabl
ii
overal
frequenc
haa
case
acut
viral
hepat
per
cent
control
popul
tabl
iii
per
cent
hospit
personnel
patient
without
liver
diseas
haa
blood
low
frequenc
seen
patient
liver
diseas
hepat
clearli
unrel
viral
hepat
patient
without
liver
diseas
frequenc
haa
blood
donor
new
york
per
cent
differ
group
blood
donor
tokyo
per
cent
tabl
ii
patient
viral
hepat
show
variabl
frequenc
posit
test
haa
depend
differ
number
sampl
taken
per
patient
stage
diseas
serum
test
also
technic
use
measur
haa
highest
frequenc
found
sampl
earli
cours
diseas
rather
late
activ
phase
convalesc
phase
one
sampl
taken
weekli
interv
sensit
technic
complement
fixat
cf
use
rather
immunodiffus
technic
ident
haaposit
longincub
hepat
gener
frequenc
haa
greater
patient
document
posttransfus
postinject
hepat
patient
histori
parenter
exposur
seri
patient
test
earli
acut
phase
diseas
frequenc
haa
vari
per
cent
hepat
acquir
parenter
per
cent
sporad
case
hepat
consid
infecti
tabl
ii
none
patient
list
tabl
ii
involv
socal
singl
sourc
outbreak
shortincub
infecti
hepat
well
document
epidem
shortincub
viral
hepat
involv
person
person
spread
yet
associ
posit
test
haa
diagnosi
serum
hepat
establish
certainti
incub
period
parenter
exposur
reason
histori
parenter
exposur
diagnosi
usual
consid
infecti
hepat
even
sourc
infect
incub
period
uncertain
therefor
tabl
ii
longincub
shortincub
viral
hepat
case
doubt
includ
group
patient
diagnosi
infecti
hepat
view
follow
evid
longincub
type
viral
hepat
associ
haa
shortincub
type
type
transmit
parenter
oral
possibl
haaposit
case
list
tabl
ii
diagnosi
infecti
hepat
longincub
hepat
earli
work
oral
nasopharyng
transmiss
longincub
hepat
equivoc
neg
howev
noteworthi
epidemiolog
studi
indic
form
hepat
spread
intim
contact
recent
report
epidem
longincub
hepat
patient
staff
renal
dialysi
unit
sug
gest
person
person
spread
epidemiolog
experiment
observ
krugman
cowork
indic
institut
endem
longincub
hepat
transmit
nonparenter
studi
krugman
et
al
clearli
demonstr
two
distinct
hepat
agent
one
respons
longand
shortincub
hepat
shortincub
agent
call
produc
hepat
thirtyf
fortyseven
day
inject
feed
infecti
serum
stool
filtrat
wherea
longincub
agent
call
produc
hepat
fortyon
day
inject
approxim
seventi
day
feed
infecti
serum
noteworthi
oral
dose
necessari
produc
delay
longincub
hepat
fiftyfold
higher
pa
figur
patient
okochi
murakami
gock
kavey
durat
haa
gock
kavey
seri
estim
data
given
haa
seri
measur
agar
gel
diffus
renter
dose
indic
infect
markedli
decreas
agent
transmit
oral
gile
cowork
found
almost
patient
given
longincub
agent
haa
serum
incub
period
acut
stage
hepat
wherea
patient
given
shortincub
agent
never
haa
serum
tabl
il
experi
haa
found
patient
diagnos
serum
infecti
hepat
ident
immunolog
specif
short
incub
infecti
hepat
longincub
serum
hepat
known
confer
homolog
heterolog
immun
agent
krugman
et
al
thu
least
two
viral
agent
caus
clinic
manifest
hepat
transmit
way
one
longincub
period
produc
haa
wherea
short
incub
period
yet
defin
immunolog
appear
persist
haa
tempor
relationship
exposur
hepat
appear
haa
blood
develop
symptom
abnorm
liver
function
test
well
document
studi
involv
serum
specimen
collect
sixti
subject
inocul
icterogen
plasma
hepat
transmiss
experi
carri
figur
cumul
plot
time
subject
jaundic
develop
complement
fixat
immunodiffus
test
haa
becam
posit
figur
show
durat
haa
patient
addit
patient
studi
investig
sensit
complement
fixat
technic
haa
appear
averag
four
week
clinic
laboratori
evid
liver
dysfunct
although
interv
vari
individu
case
one
day
seven
week
krugman
gile
use
complement
fixat
technic
found
haa
appear
two
week
two
month
abnorm
level
serum
glutam
oxal
transaminas
sgot
patient
inocul
hepat
agent
less
sensit
agar
gel
diffus
technic
detect
haa
two
week
complement
fixat
technic
figur
time
elev
serum
glutam
pyruv
transaminas
sgpt
could
measur
haa
appear
incub
period
experiment
hepat
persist
almost
case
onset
symptom
abnorm
liver
function
test
case
natur
occur
hepat
serum
obtain
first
week
acut
phase
like
posit
haa
although
among
patient
studi
cossart
vahrman
antigen
develop
patient
second
week
ill
persist
antigen
blood
figur
american
journal
medicin
found
number
investig
rang
day
mani
year
case
haa
disappear
symptom
subsid
biochem
abnorm
return
normal
although
case
revers
true
signific
differ
durat
haa
eighti
patient
diagnos
serum
hepat
figur
six
patient
diagnos
gock
kavey
infecti
hepat
patient
diagnos
cossart
vahrman
serum
infecti
hepat
subject
inocul
agent
variou
studi
appear
consist
correl
persist
antigen
sixteen
week
time
haa
first
detect
blood
titer
haa
sever
hepat
carrier
state
eightysix
haaposit
patient
experiment
hepat
transmiss
studi
figur
eight
antigen
blood
sixteen
week
still
present
serum
sampl
eight
taken
three
year
later
studi
krugman
gile
per
cent
institution
children
posit
test
haa
inocul
agent
retain
antigen
serum
mani
month
mani
year
frequenc
haa
persist
twentyfour
month
asymptomat
adult
patient
institut
approxim
per
cent
ordinarili
haa
could
detect
patient
four
month
onset
acut
hepat
present
indefinit
observ
retain
haa
recov
acut
ill
routin
fashion
either
mild
laboratori
clinic
evid
hepat
time
haa
still
present
four
month
mani
year
later
although
persist
antigen
may
occur
hepat
degre
sever
appear
occur
commonli
mild
subclin
hepat
overt
clinic
diseas
henc
mani
carrier
haa
rnay
unawar
anteced
episod
acut
hepat
keep
recent
observ
asymptomat
subject
haa
blood
also
histolog
evid
chronic
liver
diseas
even
liver
function
test
includ
transaminas
valu
normal
histori
anteced
hepat
frequenc
subclin
chronic
hepat
judg
incid
haa
appar
healthi
popul
would
per
cent
unit
state
per
cent
mani
tropic
region
high
per
cent
certain
endem
area
evid
suggest
subclin
chronic
hepat
occur
frequent
lower
dose
infecti
viru
see
section
relationship
viral
dose
mode
transmiss
sever
hepat
haa
symptomat
chronic
liver
diseas
progress
chang
serial
liver
biopsi
specimen
acut
viral
hepat
cirrhosi
well
document
recent
sherlock
cowork
observ
chang
ten
month
period
test
haa
remain
posit
sinc
haaposit
acut
viral
hepat
fol
low
spectrum
chronic
liver
lesion
surpris
high
frequenc
haa
associ
certain
categori
chronic
liver
diseas
tabl
iv
high
frequenc
haa
prolong
viral
hepat
whether
lesion
unresolv
classic
hepat
subacut
hepat
necrosi
tabl
iv
differ
patient
asymptomat
carrier
haa
appear
one
degre
hepat
involv
level
haa
seem
vari
fluctuat
liver
function
test
relat
degre
abnorm
test
sever
symptom
haa
occasion
observ
disappear
face
persist
symptom
abnorm
laboratori
test
tend
persist
even
activ
diseas
suppress
adren
corticosteroid
therapi
instanc
haa
present
blood
subject
liver
biopsi
histolog
lesion
chronic
hepat
found
even
remiss
symptom
abnorm
liver
function
test
patient
london
chronic
persist
hepat
haa
blood
howev
one
patient
studi
one
seri
infecti
hepat
rather
serum
hepat
initi
ill
high
proport
patient
london
seri
probabl
infecti
hepat
wherea
epidemiolog
evid
serum
hepat
everi
case
prolong
hepat
studi
wright
et
al
unit
state
chronic
activ
hepat
although
case
chronic
activ
hepat
cah
activ
chronic
hepat
appear
result
unresolv
viral
hepat
cah
seem
syndrom
rather
singl
diseas
mani
case
categori
appear
close
relat
lupuslik
disord
sever
studi
unit
state
per
cent
patient
cah
posit
test
haa
titer
haa
patient
cah
patient
acut
viral
hepat
ie
usual
greater
complement
fixat
contrast
transient
natur
haa
acut
hepat
titer
tend
remain
constant
mani
month
sever
year
cah
despit
fluctuat
liver
function
test
face
variou
form
treatment
includ
adren
corticosteroid
howev
haa
disappear
sever
patient
cah
period
mani
month
clinic
improv
occur
although
patient
cah
predominantli
femal
cah
circul
haa
predominantli
male
usual
anteced
episod
acut
hepat
strong
histori
parenter
exposur
although
per
cent
patient
cah
posit
lupu
erythematosu
cell
phenomenon
much
lower
per
cent
patient
cah
haa
posit
lupu
erythematosu
cell
test
almost
report
patient
cah
posit
lupu
erythematosu
cell
test
posit
test
haa
thu
test
haa
seem
differenti
two
group
patient
categori
cah
haaposit
group
like
progress
acut
viral
hepat
lupu
erythematosusposit
haaneg
group
probabl
repres
immunolog
aberr
lupuslik
featur
subdivis
cah
case
way
may
prove
prognost
therapeut
import
particularli
respect
use
ad
renocorticosteroid
similar
case
cah
england
australia
associ
posit
test
haa
sinc
level
haa
posit
case
unit
state
usual
high
easi
detect
even
weak
antibodi
technic
differ
seem
account
discrep
perhap
cah
unit
state
often
sequela
haaposit
viral
hepat
countri
type
hepat
preval
cirrhosi
cryptogen
cirrhosi
inact
postnecrot
cirrhosi
instanc
may
repres
inact
phase
cah
heal
stage
acut
viral
hepat
low
incid
ofhaa
tabl
iv
although
consid
acut
viral
hepat
may
etiolog
case
primari
biliari
cirrhosi
diseas
like
relat
haaposit
form
hepat
eightythre
case
studi
two
group
investig
neg
haa
tabl
iv
laennec
alcohol
cirrhosi
associ
haa
unless
patient
receiv
transfus
tabl
iii
recent
princ
burk
report
posit
test
haa
nine
ten
patient
primari
biliari
cirrhosi
use
high
voltag
counterelectrophoresi
technic
found
posit
reaction
lower
voltag
technic
found
high
voltag
low
voltag
technic
ident
sensit
high
voltag
technic
accord
princ
burk
subject
fals
posit
reaction
perhap
basi
appar
increas
sensit
high
voltag
low
voltag
technic
also
discrep
result
biliari
cirrhosi
other
condit
possibl
predispos
haaposit
hepat
number
report
blumberg
cowork
suggest
patient
syndrom
lepromat
leprosi
leukemia
uremia
high
frequenc
haabecaus
unusu
suscept
hepat
virtu
genet
acquir
immunolog
defect
moreov
basi
extens
famili
studi
blumberg
et
al
conclud
presenc
haa
blood
determin
autosom
recess
trait
view
follow
consider
interpret
may
reject
favor
stress
environment
factor
transmiss
persist
diseas
syndrom
blumberg
cowork
found
approxim
per
cent
eightyfour
patient
syndrom
haa
serum
highest
frequenc
found
differ
categori
patient
test
subsequ
studi
sutnick
et
al
indic
frequenc
haa
syndrom
highest
patient
larg
institut
per
cent
rel
low
patient
small
institut
per
cent
detect
noninstitution
patient
disord
controi
similarli
retard
patient
institut
per
cent
frequenc
haao
patient
syndrom
haa
serum
gener
mildli
elev
sgpt
level
normal
bilirubin
level
liver
function
test
underw
biopsi
show
histolog
evid
chronic
viral
hepat
find
interpret
indic
patient
syndrom
uniqu
suscept
hepat
hepat
transmit
oral
larger
institut
environ
seem
less
hygien
smaller
institut
conclud
environment
well
genet
ierhap
immunolog
host
factor
involv
krugman
gile
find
higher
frequenc
haa
adult
patient
syndrom
patient
age
group
similar
mental
retard
consid
highep
frequenc
haa
children
syndrom
result
admit
earlier
age
mental
retard
children
ambulatori
henc
expos
environment
factor
respons
transmit
hepat
longer
period
patient
also
suggest
studi
blumberg
et
al
base
singl
bleed
might
reflect
accur
overal
epidemiolog
hepat
institut
studi
epidemiolog
studi
carri
long
period
szmuness
cowork
institut
transmiss
haaposit
viral
hepat
patient
syndrom
form
mental
retard
led
conclud
krugman
gile
occurr
distribut
persist
haa
institution
mental
retard
patient
type
influenc
age
patient
expos
durat
exposur
etiolog
mental
retard
lepromat
leprosi
blumberg
sugggst
patient
lepromat
leprosi
high
frequenc
haa
abnorm
immun
respons
possibl
genet
determin
predispos
number
ill
includ
viral
hepat
lepromat
leprosi
leukemia
frequenc
haa
patient
lepromat
leprosi
per
cent
seventyon
patient
borderlin
lepromat
leprosi
per
cent
wherea
patient
tuberculoid
leprosi
per
cent
appar
normal
person
nearbi
popul
per
cent
differ
consid
signific
despit
high
frequenc
haa
control
popul
moreov
almost
lepromat
leprosi
patient
confin
leprosarium
wherea
patient
tuberculoid
leprosi
almost
outpati
well
known
haa
preval
institution
patient
syndrom
outpati
case
institution
mental
retard
patient
preval
haa
institution
lepromat
leprosi
case
highest
youngest
age
group
suggest
syndrom
age
exposur
intimaci
exposur
durat
exposur
endem
hepat
import
genet
immunolog
factor
determin
preval
haa
renal
dialysi
patient
receiv
longterm
hemodialysi
cite
exampl
peopl
impair
immun
mechan
alter
usual
manifest
hepat
seventeen
patient
mainten
hemodialysi
studi
turner
white
eight
eventu
definit
posit
test
haa
two
eight
clinic
evid
hepat
four
anicter
hepat
two
usual
manifest
symptomat
hepat
icteru
none
receiv
immunosuppress
therapi
two
half
year
period
case
collect
hepat
develop
eleven
nurs
technician
staff
hemodialysi
unit
seven
nine
whose
blood
avail
within
first
two
week
onset
haa
serum
ten
eleven
affect
staff
member
typic
hepat
develop
elev
bilirubin
level
contrast
chiefli
asymptomat
anicter
hepat
patient
dialysi
posit
test
haa
dialysi
patient
persist
long
test
four
month
two
year
wherea
haa
disappear
within
four
week
blood
staff
member
hepat
blumberg
cowork
also
observ
anicter
hepat
persist
haa
eight
patient
receiv
longterm
hemodialysi
acut
viral
hepat
icteru
transient
haa
develop
six
staff
member
dialysi
unit
thu
two
studi
patient
uremia
longterm
dialysi
anicter
hepat
develop
persist
haa
wherea
normal
subject
contract
hepat
intim
contact
urem
patient
typic
acut
hepat
transient
haa
sourc
hepat
patient
doubt
transfus
blood
howev
other
may
receiv
low
dose
viru
parenter
oral
contamin
whether
staff
member
infect
parenter
otherwis
known
sinc
sever
diseas
durat
haa
may
relat
dose
infecti
agent
see
section
transmiss
differ
manifest
hepat
patient
staff
may
attribut
much
differ
dose
infecti
agent
possibl
rout
infect
host
respons
mention
dialysi
unit
problem
hepat
patient
staff
inherit
trait
earli
studi
inherit
haa
carri
antigen
consid
protein
allotyp
call
au
show
segreg
antigen
famili
consist
simpl
autosom
recess
inherit
later
statist
analysi
occurr
haa
famili
member
differ
popul
show
highli
signific
agreement
genet
hypothesi
sinc
much
inform
suggest
haa
link
infecti
agent
find
consid
compat
inherit
suscept
number
chronic
infect
includ
agent
prouc
haa
predomin
antigen
male
subject
decreas
preval
older
age
group
explain
factor
might
affect
suscept
resist
gel
diffus
technic
use
detect
haa
genet
studi
rel
insensit
appar
observ
valu
haaposit
famili
member
would
two
three
time
higher
sensit
complement
fixat
counterelectrophoret
technic
use
valu
would
agre
close
calcul
theoret
valu
autosom
recess
inherit
studi
perform
sensit
test
haa
see
whether
evid
recess
inherit
suscept
hepat
upheld
clinic
valu
test
haa
differenti
diagnosi
sinc
haa
specif
manifest
agent
longincub
hepat
test
haa
use
differenti
two
major
type
viral
hepat
posit
haa
test
defin
form
hepat
precis
haaposit
hepat
howev
diagnosi
haaneg
hepat
made
basi
neg
haa
test
antigen
may
present
transient
level
low
detect
current
method
measur
patient
assum
haaneg
hepat
known
incub
period
short
term
serum
infecti
seem
ambigu
describ
hepat
probabl
use
obscur
chronic
liver
diseas
test
haa
may
posit
valuabl
establish
diagnosi
variant
usual
clinic
manifest
longincub
hepat
decept
moreov
least
one
diagnost
categori
chronic
liver
diseas
cah
base
chiefli
hepat
histolog
subdivid
haaposit
case
like
sequela
longincub
hepat
haaneg
ase
may
may
consequ
viral
hepat
prognosi
keep
gener
impress
longincub
hepat
usual
sever
shortincub
hepat
cossart
vahrmam
found
per
cent
patient
haaposit
hepat
prolong
hospit
cours
sgot
remain
usual
unit
eighth
week
compar
haaneg
hepat
usual
sgot
valu
unit
fifth
week
sequenti
test
acut
hepat
may
help
prognosi
unusu
long
persist
haa
indic
progress
chronic
hepat
whether
symptom
subsid
laboratori
test
becom
normal
differenti
cah
case
haaposit
haaneg
posit
lupu
erythematosu
test
may
prove
valuabl
prognost
therapeut
prophylaxi
sinc
pool
normal
gamma
globulin
effect
prophylact
shortincub
haaneg
hepat
offer
littl
protect
longincub
haaposit
hepat
document
haa
case
acut
hepat
would
obviat
need
give
prophylact
gamma
globulin
patient
contact
also
identifi
type
hepat
establish
specif
immun
develop
high
degre
immun
although
absolut
homolog
viru
cross
immun
longincub
haaposit
shortincub
haaneg
hepat
highli
sensit
test
specif
antihaa
current
investig
see
section
immun
may
permit
identifi
specif
prior
hepat
infect
test
haa
may
use
screen
patient
medic
staff
situat
predispos
endem
frequent
iatrogen
hepat
eg
renal
dialysi
unit
institut
mental
retard
group
patient
given
multipl
transfus
knowledg
carrier
state
may
help
prevent
contact
case
reason
posit
transmit
hepat
food
handler
surgeon
dentist
probabl
test
haa
import
applic
screen
test
identif
blood
donor
carrier
haa
al
evid
indic
haaposit
blood
transmit
hepat
see
section
transmiss
current
avail
test
haa
antihaa
valuabl
within
limit
sensit
purpos
realiz
posit
test
signific
test
simpl
inexpens
employ
routin
laboratori
procedur
hospit
blood
bank
direct
evid
haa
infecti
agent
physic
chemic
characterist
antigen
materi
suggest
chiefli
noninfecti
empti
viru
coat
amount
haa
circul
great
small
fraction
would
infecti
virion
approach
blood
concentr
viru
characterist
viral
ill
yet
known
laboratori
anim
use
pass
agent
appropri
haa
anim
outbreak
hepat
among
handler
higher
ape
occurr
diseas
similar
human
hepat
chimpanze
irapl
ape
hepat
carrier
appar
normal
chimpanze
higher
ape
rel
high
frequenc
haa
blood
tabl
v
seven
chimpanze
carrier
haa
histolog
evid
mild
activ
hepat
biopsi
antigen
immunolog
indistinguish
haa
found
human
serum
detect
seven
chimpanze
three
orangutan
three
gibbon
sever
speci
monkey
although
other
mention
presenc
haa
r
monkey
marmoset
monkey
use
possibl
anim
model
human
viral
hepat
even
anim
liver
lesion
inocul
blood
hepat
patient
found
haa
serum
accord
recent
report
marmoset
may
susceptibe
infect
shortincub
hepat
viru
rather
type
produc
haa
known
whether
haaposit
hepat
natur
infect
higher
ape
whether
acquir
infect
contact
man
common
practic
anim
dealer
give
infant
ape
transfus
human
blood
transfus
okochi
murakami
note
develop
haaposit
hepat
three
recipi
antigenposit
blood
also
found
antigen
six
posttransfus
hepat
patient
receiv
antigenposit
blood
failur
detect
haa
transfus
blood
consid
reflect
insensit
agar
gel
technic
gock
et
al
retrospect
studi
twelv
patient
receiv
antigenposit
blood
found
hepat
develop
nine
serum
seven
nine
posit
haa
recent
gock
found
frequenc
hepat
forti
patient
given
transfus
blood
contain
haa
approxim
per
cent
wherea
four
case
hepat
seen
sixtynin
recipi
antigenneg
blood
gile
demonstr
regular
appear
haaposit
hepat
recipi
haa
posit
serum
obtain
patientduringth
acut
phase
longincub
hepat
also
observ
appar
second
passag
haa
two
subject
receiv
serum
donor
inocul
agent
asymp
note
inocul
ml
subcutan
inocul
materi
concentr
cesium
chlorid
gradient
found
contain
viruslik
particl
characterist
haa
electronmicroscopi
data
taken
barker
et
al
acut
phase
serum
obtain
ten
day
appear
clinic
symptom
icteru
subject
inocul
ninetyfour
day
prior
time
icterogen
plasma
pool
contain
haa
immunolog
electronmicrograph
criteria
donor
suspect
hepat
carrier
hepat
develop
recipi
blood
although
donor
histori
liver
diseas
thrombin
suspect
transmit
hepat
clinic
use
haa
could
detect
undilut
plasma
agar
gel
diffus
viruslik
particl
typic
haa
seen
electronmicroscopi
plasma
concentr
cesium
chlorid
gradient
data
taken
barker
et
al
tomat
carrier
haa
almost
four
year
inocul
studi
involv
recipi
barker
et
al
show
plasma
purifi
plasma
protein
contain
haa
transmit
haaposit
hepat
tabl
vi
materi
produc
hepat
weekli
serum
sampl
obtain
inocul
subject
store
time
transmiss
studi
analyz
haa
haa
viruslik
particl
characterist
haa
present
inocul
materi
recipi
hepat
develop
also
haa
blood
incub
period
acut
phase
diseas
mani
recipi
clinic
laboratori
evid
hepat
develop
nevertheless
haa
serum
haa
appear
asymptomat
recipi
delay
consist
incub
period
hepat
experi
acut
phase
serum
tabl
vi
document
second
passag
haaposit
hepat
serum
haaposit
donor
hepat
develop
inocul
haaposit
plasma
pool
tabl
vii
addit
observ
barker
et
al
indic
recipi
low
dose
infecti
viru
plasma
dilut
tabl
vii
mild
ill
anicter
frequent
subclin
hepat
haa
unusu
long
incub
period
tend
retain
antigen
indefinit
twelv
subject
becam
persist
carrier
haa
particip
hepat
transmiss
studi
eight
minim
symptom
hepat
bilirubin
elev
greater
mg
remain
four
symptom
laboratori
abnorm
other
also
observ
prolong
incub
period
hepat
administr
low
infecti
dose
note
hepat
develop
usual
mild
anicter
observ
impli
convers
mild
subclin
hepat
develop
retain
haa
unusu
long
period
like
infect
rel
low
dose
viru
subject
prone
develop
persist
circul
haa
without
signific
liver
diseas
viz
patient
syndrom
lepromat
leprosi
hemodialysi
patient
carrier
tropic
popul
haa
preval
may
infect
low
dose
viru
may
necessarili
unusu
suscept
hepat
addit
observ
relat
mode
transmiss
sever
diseas
appar
infecti
dose
mirick
shank
epidem
longincub
hepat
appear
spread
person
person
contact
usual
anicter
krugman
szmuness
et
al
institut
transmiss
haaposit
hepat
appar
contact
requir
long
period
exposur
suggest
low
infect
appar
dilut
studi
tabl
vii
haa
viru
particl
respons
hepat
minimum
amount
transmit
hepat
far
detect
sensit
test
haa
current
avail
haa
undilut
icterogen
plasma
pool
titer
complement
fixat
viruslik
particl
visibl
electronmicroscopi
plasma
concentr
cesium
chlorid
gradient
undilut
plasma
gave
neg
test
haa
agar
gel
nevertheless
overt
clinic
haaposit
hepat
transrflit
ml
dilut
plasma
appar
subclin
hepat
judg
replic
haa
transmit
ml
plasma
dilut
high
compar
sensit
laboratori
test
current
avail
biolog
test
haa
transmiss
hepat
man
sensit
factor
approxim
high
infect
viru
parenter
rout
suggest
hepat
caus
amount
blood
could
transfer
hematophag
insect
insect
vector
whether
bed
bug
lous
mosquito
could
account
transmiss
appear
involv
person
person
contact
institut
tropic
region
haa
carrier
preval
ad
weight
possibl
recent
find
princ
tropic
popul
africa
asia
south
america
haa
ten
hundr
time
preval
new
york
signific
differ
preval
haa
male
femal
subject
appar
declin
increas
age
frequenc
serum
contain
antigen
definit
inform
transplacent
transmiss
haaposit
hepat
three
patient
perinat
hepat
whose
mother
haaposit
hepat
pregnanc
found
haa
blood
cord
blood
two
infant
whose
mother
haaposit
time
deliveri
neg
antigen
cord
blood
infant
test
transplacent
transmiss
seem
less
like
infect
infant
shortli
birth
attempt
identifi
haa
bodi
fluid
blood
view
appar
transmiss
longincub
hepat
person
person
contact
circumst
possibl
consid
infect
may
occur
via
fecalor
rout
urin
pharyng
secret
howev
earli
attempt
identifi
agent
longincub
hepat
fece
nasopharyng
secret
human
transmiss
studi
success
recent
attempt
measur
haa
directli
variou
bodi
fluid
also
success
patient
haa
blood
could
measur
dilut
greater
complement
fixat
technic
detect
haa
saliva
concentr
tenfold
urin
concentr
hundredfold
per
cent
stool
extract
although
haa
found
extract
stool
patient
haa
serum
differ
protein
antigen
associ
hepat
found
extract
new
antigen
precipit
agar
gel
diffus
electrophoret
test
serum
per
cent
patient
receiv
multipl
transfus
patient
haaposit
acut
viral
hepat
antigen
found
extract
stool
five
five
patient
acut
viral
hepat
two
five
patient
chronic
hepat
one
patient
receiv
multipl
transfus
stool
extract
twentyf
normal
subject
patient
without
liver
diseas
shown
figur
materi
stool
appear
share
antigen
determin
haa
although
half
serum
precipit
stool
antigen
contain
antihaa
antigen
appear
protein
molecular
weight
associ
hepat
new
antigen
could
alter
compon
viru
produc
haa
differ
viral
agent
may
complement
accompani
viru
detail
report
new
antigen
forthcom
haa
plasma
fraction
cohn
cold
ethanol
plasma
fraction
except
fraction
ii
contain
measur
amount
haa
unfraction
plasma
heavili
contamin
antigen
tabl
find
corrobor
extens
clinic
experi
indic
fraction
ii
pool
normal
gamma
globulin
transmit
hepat
wherea
fraction
fibrinogen
iii
thrombin
implic
often
fraction
ii
probabl
contain
signific
amount
specif
antibodi
haa
attempt
neutral
longincub
hepat
agent
fraction
ii
measur
antihaa
fraction
ii
success
fraction
v
albumin
contain
rel
small
amount
haa
haa
albumin
remain
immunolog
stabl
precipit
test
albumin
heat
ten
hour
sinc
heat
albumin
transmit
serum
hepat
simpli
find
posit
test
haa
necessarili
indic
infect
hand
failur
find
haa
plasma
fraction
give
assur
fraction
free
infecti
agent
mani
commerci
fraction
prepar
known
transmit
longincub
hepat
contain
detect
amount
antigen
agar
gel
complement
fixat
technic
assum
pool
plasma
prepar
commerci
fraction
pool
plasma
except
gamma
globulin
contain
suffici
viru
transmit
hepat
insuffici
haa
detect
vitro
test
transmiss
experi
shown
tabl
vii
preval
haa
differ
blood
donor
popul
measur
insensit
agar
gel
diffus
tabl
complement
fixat
technic
least
hundredfold
sensit
agar
gel
diffus
detect
approxim
twice
mani
haa
carrier
among
blood
donor
estim
insensit
agar
gel
diffus
technic
detect
per
cent
carrier
popul
among
blood
donor
estim
correct
screen
complement
fixat
possibl
elimin
least
per
cent
donor
transmit
hepat
experi
counterelectrophoret
technic
approxim
ten
time
sensit
agar
gel
diffus
tento
twentyfold
less
sensit
complement
fixat
detect
haa
carrier
complement
fixat
technic
thu
appear
haa
carrier
detect
technic
ten
time
sensit
simpl
agar
gel
diffus
addit
sensit
complement
fixat
technic
appear
reveal
significantli
greater
number
although
studi
necessari
indic
carrier
tend
level
haa
easili
detect
current
avail
simpl
inexpens
test
screen
donor
haa
technic
equival
sensit
counterelectrophoresi
complement
fixat
seem
necessari
function
blood
bank
associ
presenc
haa
transmiss
hepat
conclus
anamnest
antibodi
antibodi
use
diagnost
measur
haa
precipitin
complement
fixat
technic
come
patient
receiv
multipl
transfus
high
titer
hyperimmun
antihaa
develop
appar
result
repeat
exposur
antigen
transfus
blood
okochi
murakami
use
agar
gel
precipitin
technic
observ
fifteen
instanc
antihaa
appear
transfus
haaposit
blood
addit
seven
instanc
antihaa
appear
follow
transfus
blood
haa
found
circumst
consid
reflect
insensit
method
measur
haa
fourteen
patient
antibodi
develop
within
two
week
six
patient
two
four
week
transfus
remain
two
patient
antibodi
detect
fiftysix
sixti
day
transfus
respect
develop
rel
high
titer
antihaa
shortli
transfus
suggest
antibodi
respons
anamnest
shown
figur
detect
haa
usual
appear
blood
five
week
inocul
infecti
plasma
whether
notth
hepat
develop
patient
receiv
transfus
whether
histori
prior
hepat
transfus
mention
studi
okochi
murakami
other
note
appar
anamnest
appear
complementfix
antihaa
within
two
week
transfus
krugman
gile
also
observ
occasion
low
titer
complement
fixat
antihaa
patient
reexpos
haaposit
serum
year
initi
exposur
variou
observ
suggest
antibodi
measur
agar
gel
precipitin
complement
fixat
technic
aris
commonli
clinic
condit
permit
anamnest
respons
antibodi
type
rare
detect
cours
primari
acut
chronic
hepat
infect
antihaa
acut
chronic
hepat
none
mani
case
acut
chronic
hepat
studi
wright
et
al
tabl
ii
iv
antihaa
detect
agar
gel
precipitin
technic
develop
cossart
vahrman
find
antibodi
complement
fixat
technic
serum
obtain
convalesc
state
two
patient
haaposit
acut
hepat
use
haa
present
homolog
serum
antigen
krugman
gile
find
antihaa
complement
fixat
primari
acut
haaposit
hepat
larg
seri
experiment
infect
patient
shulman
et
al
test
serum
obtain
weekli
interv
twentytwo
patient
haaposit
hepat
one
two
month
period
onset
diseas
found
one
antibodi
detect
agar
gel
precipitin
technic
two
antibodi
low
titer
detect
complement
fixat
none
sixti
addit
patient
one
two
random
sampl
obtain
recoveri
phase
acut
hepat
chronic
hepat
antibodi
complement
fixat
agar
gel
precipitin
technic
howev
recent
develop
highli
sensit
hemagglutin
test
antihaa
mani
eightytwo
patient
acut
chronic
hepat
found
antibodi
tabl
viii
hemagglutin
test
involv
coat
red
cell
isol
haa
agglutin
cell
antihaa
approxim
sensit
agar
gel
precipitin
test
approxim
hundredfold
sensit
complement
fixat
test
measur
antibodi
hemagglutin
test
frequenc
antihaa
format
patient
recov
haaposit
acut
hepat
approxim
per
cent
patient
prolong
hepat
per
cent
chronic
activ
hepat
per
cent
antibodi
detect
three
four
case
hepat
associ
drug
use
may
reflect
anamnest
respons
intermitt
reexposur
antigen
presenc
antihaa
seem
influenc
cours
sever
diseas
signific
antigenantibodi
complex
special
note
find
haa
occasion
measur
presenc
antihaa
patient
recov
acut
hepat
tabl
viii
haa
measur
rel
low
titer
complement
fixat
face
rel
high
titer
antibodi
complement
fixat
circumst
may
reflect
readili
revers
antigenantibodi
complex
involv
high
concentr
low
avid
antibodi
two
instanc
haa
measur
presenc
antihaa
case
chronic
activ
hepat
antibodi
low
tite
r
n
re
pe
ctive
ly
hemagglutin
technic
haa
measur
presenc
antibodi
one
instanc
low
titer
complement
fixat
instanc
high
titer
complement
fixat
antigen
coat
red
cell
use
hemagglutin
test
effect
compet
antigenantibodi
complex
antihaa
probabl
cell
agglutin
form
favor
competit
reaction
although
antigen
antibodi
could
measur
directli
mani
patient
presenc
antigenantibodi
complex
often
reflect
anticomplementari
activ
anticomplementari
activ
abil
serum
alon
without
addit
antigen
antibodi
inactiv
complement
exampl
characterist
tempor
relationship
develop
anticomplementari
activ
appear
circul
haa
occur
three
patient
hepat
develop
receiv
transfus
shown
figur
find
suggest
antigenantibodi
complex
capabl
fix
complement
appear
earli
cours
diseas
longer
fix
complement
antigen
excess
regain
abil
fix
complement
antigen
antibodi
ratio
decreas
evid
anticomplementari
activ
caus
antigenantibodi
complex
presenc
viruslik
particl
anticomplementari
serum
neutral
anticomplementari
activ
addit
excess
purifi
haa
appear
chang
complex
noncompl
fix
antigenexcess
form
abil
organ
solvent
revers
antigenantibodi
complex
decreas
anticomplementari
activ
permit
immunolog
detect
haa
treat
serum
almeida
waterson
interpret
electronmicrograph
serum
specimen
obtain
patient
differ
form
haaposit
hepat
show
either
randomli
distribut
particl
indic
free
antigen
clump
particl
suggest
immun
complex
consid
possibl
differenti
electronmicroscopi
complex
form
antigen
antibodi
excess
recent
millman
cowork
also
obtain
evid
immunodiffus
technic
haa
antihaa
present
togeth
serum
patient
viral
hepat
presenc
antigenantibodi
complex
patient
viral
hepat
depress
complement
level
instanc
acut
phase
ill
suggest
certain
multisystem
manifest
hepat
may
immun
natur
exampl
acut
arthralgia
artlriti
mya
gia
rash
urticaria
gener
vascul
hyperglobulinemia
may
accompani
acut
chronic
viral
hepat
may
manifest
circul
antigenantibodi
complex
bulkley
et
al
found
high
frequenc
arthriti
arthralgia
among
patient
chronic
activ
hepat
whose
serum
posit
haa
alpert
et
al
found
serum
complement
level
patient
acut
hepat
depress
arthralgia
arthriti
associ
either
fever
urticaria
circul
haa
gock
et
al
observ
four
patient
polyarthr
circul
haa
basi
immunofluoresc
studi
possibl
deposit
haa
complex
antibodi
small
blood
vessel
known
attack
acut
viral
hepat
confer
high
degre
immun
homolog
form
hepat
immun
absolut
indic
follow
observ
correl
antihaa
level
incub
period
hepat
antibodi
aris
without
prevent
develop
haa
progress
diseas
figur
hepat
even
follow
mark
anamnest
antibodi
respons
figur
circumst
diseas
mild
patient
whose
data
appear
figur
treat
cryoprecipit
donor
one
week
period
within
five
day
start
therapi
antihaa
appear
patient
serum
reach
peak
titer
within
two
week
approxim
two
month
later
antibodi
decay
anicter
mild
hepat
develop
elev
sgot
sgpt
level
krugman
report
similar
case
accident
reinfect
haaposit
materi
elicit
transient
antihaa
respons
follow
anicter
mild
hepat
elev
sgot
valu
circul
haa
two
similar
instanc
hepat
follow
appear
anamnest
antibodi
respons
also
report
holland
et
al
two
patient
also
mild
anicter
hepat
decay
antihaa
appear
within
two
week
transfus
describ
third
patient
sever
hepat
presenc
high
titer
antihaa
cytomegaloviru
infect
could
rule
variou
observ
suggest
usual
antihaa
probabl
effect
neutral
antibodi
clear
whether
immun
due
part
antibodi
entir
thymusdepend
system
exampl
measl
pool
normal
gamma
globulin
seem
protect
haaposit
hepat
compar
high
degre
effect
protect
shortincub
hepat
may
modifi
sever
diseas
find
circul
complex
antibodi
viral
antigen
novel
human
diseas
circul
virusantibodi
complex
well
document
anim
exampl
mice
lactic
dehydrogenas
viru
ldv
stimul
antibodi
combin
viru
virusantibodi
complex
remain
infecti
anim
lifelong
viremia
presenc
antildv
ldvantibodi
complex
rel
resist
neutral
antibodi
complex
transmit
diseas
inocul
anim
moreov
heterolog
nonneutr
antibodi
elicit
bycertain
virus
forexampl
rabbit
antiherp
simplex
viru
hsv
form
complex
viru
prevent
viral
infect
case
complex
ldv
hsv
antibodi
complex
haa
antihaa
appear
retain
infect
persist
haa
low
grade
hepat
follow
low
dose
viru
develop
chronic
hepat
follow
acut
infect
may
involv
variat
immun
respons
present
assess
possibl
use
antihaa
therapeut
sever
hepat
attract
view
follow
consider
would
difficult
predict
outcom
level
haa
correl
sever
ill
human
antihaa
antiserum
appear
neutral
infect
intracellular
viru
would
affect
antibodi
larg
amount
antibodi
would
need
bind
usual
amount
haa
circul
potenti
complex
haa
antihaa
would
harm
experiment
use
antiserum
appear
justifi
last
resort
use
antihaa
experiment
prophylact
agent
high
risk
patient
seem
reason
although
pool
normal
gamma
globulin
prevent
longincub
hepat
question
whether
amelior
diseas
still
open
known
dose
hyperimmun
antihaa
would
permit
critic
evalu
possibl
protect
effect
antibodi
whole
antiserum
could
use
prophylact
possibl
contain
infecti
virusantibodi
complex
purifi
gamma
globulin
free
viru
haa
use
vaccin
physic
chemic
treatment
inactiv
infecti
viru
would
doubt
elicit
specif
antibodi
perhap
confer
protect
howev
partial
protect
equival
low
dose
infect
conceiv
could
predispos
carrier
state
associ
low
grade
chronic
hepat
method
agar
gel
diffus
ouchterloni
gel
diffus
use
first
defin
haa
still
commonli
employ
technic
simplest
howev
immunodiffus
two
disadvantag
rel
insensit
slow
test
requir
one
three
day
complet
antigen
serum
produc
precipitin
line
dilut
immunodiffus
test
serum
unusu
larg
amount
antigen
dilut
much
similarli
serum
contain
antibodi
use
detect
antigen
dilut
figur
show
typic
immunodiffus
pattern
line
ident
haa
sampl
differ
sourc
use
agaros
rather
agar
gel
increas
sensit
twofold
sensit
also
increas
concentr
serum
sampl
dehydr
repeat
fill
well
estim
immunodiffus
technic
detect
per
cent
blood
donor
carrier
haa
counterelectrophoresi
gel
pesendorf
et
al
gock
howe
report
simpl
electrophoret
technic
increas
sensit
immunodiffus
test
approxim
tenfold
permit
develop
precipitin
line
within
hour
rather
day
princ
burk
report
similar
test
use
somewhat
higher
voltag
sensit
counterelectrophoresi
greater
immunodiffus
reactiv
compon
place
opposit
well
travel
toward
concentr
interfac
rather
diffus
direct
figur
show
titrat
counterelectrophoresi
serum
contain
haa
figur
show
simultan
test
antigen
antibodi
suggest
krassnitzki
et
al
patient
serum
place
well
contain
antigen
antibodi
figur
serum
posit
contain
haa
serum
posit
contain
antihaa
wherea
posit
conta
in
neither
counterelectrophoresi
test
rapid
practic
experi
detect
twice
mani
carrier
haa
blood
donor
group
immunodiffus
counterelectrophoresi
also
help
detect
antibodi
anticomplementari
serum
contain
antigenantibodi
complex
difficult
assay
complement
fixat
system
cellulos
acet
immunoelectrophoresi
saravi
et
al
report
electrophoresi
serum
cellulos
acet
membran
impregn
antihaa
test
haa
presenc
antigen
indic
precipitin
pattern
form
haaposit
serum
technic
employ
larg
amount
antibodi
difficult
perform
counterelectrophoresi
sensit
immunodiffus
cellulos
acet
test
appar
advantag
complement
fixat
complement
fixat
procedur
measur
haa
appear
sensit
rapid
avail
technic
also
uniqu
advantag
abl
detect
antigenantibodi
complex
measur
anticomplementari
activ
complement
fixat
test
measur
antigen
antibodi
quantit
qualit
complet
within
two
hour
hundredto
two
hundredfold
sensit
immunodiffus
technic
detect
antigen
twentyto
fortyfold
sensit
detect
antibodi
complement
fixat
test
haa
antihaa
autom
like
complement
fixat
test
semiquantit
qualit
complement
fixat
microtit
plate
shown
figur
perform
routin
manner
laboratori
use
method
serolog
test
recent
develop
qualit
complement
fixat
test
measur
depend
diffus
complement
agaros
gel
carri
easili
immunodiffus
test
figur
gel
contain
sensit
indic
cell
store
least
one
week
suppli
laboratori
equip
standar
reagent
variou
adapt
modif
complement
fixat
test
approxim
sensit
although
worker
use
overnight
incub
fix
complement
prolong
incub
unnecessari
maximum
complement
fixat
take
place
thirti
sixti
minut
complement
fixat
technic
sensit
technic
except
hemagglutin
detect
haa
complement
fixat
test
hemagglutin
test
equal
sensit
detect
haa
complement
fixat
test
simpler
purpos
although
complement
fixat
test
tento
twentyfold
sensit
counterelectrophoresi
detect
haa
titer
haa
blood
carrier
high
enough
detect
counterelectrophoresi
avail
suitabl
antibodi
might
limit
applic
complement
fixat
routin
test
antiserum
precipit
haa
agar
gel
suitabl
complement
fixat
howev
high
qualiti
complement
fixat
antibodi
produc
higher
ape
limit
amount
guinea
pig
hemagglutin
hemagglutin
assay
recent
develop
laboratori
involv
coat
red
cell
purifi
antigen
use
chromic
chlorid
coupl
agent
hemagglutin
reaction
perform
microtit
plate
read
pattern
agglutin
shown
figur
test
includ
coat
cell
antigen
carri
two
hour
equipmentand
reagent
except
purifi
antigen
readili
avail
blood
bank
purifi
antigen
prepar
haaposit
plasma
combin
rate
isopycn
band
cesium
chlorid
csci
densiti
gradient
stabl
indefinit
coat
cell
may
preserv
longterm
use
glutaraldehyd
red
cell
haa
attach
agglutin
extrem
small
amount
antihaa
sensit
hemagglutin
appear
least
greater
immunodiffus
hundredfold
greater
complement
fixat
approxim
radioimmunoassay
measur
antihaa
view
simplic
hemagglutin
assay
compar
radioimmunoassay
latter
appear
littl
valu
data
obtain
hemagglutin
antihaaform
acut
chronic
viral
hepat
present
tabl
viii
detect
antigen
hemagglutin
antibodi
could
produc
agglutin
dilut
mix
equal
volum
serum
suspect
contain
haa
neutral
antibodi
antigen
serum
prevent
hemagglutin
serum
sampl
test
hemagglutin
inhibit
complement
fixat
posit
complement
fixat
gave
posit
result
hemagglutin
hemagglutin
test
like
complement
fixat
lend
autom
electron
microscopi
serum
posit
haa
immunolog
test
contain
viruslik
particl
type
shown
figur
haa
serum
concentr
pellet
ultracentrifug
addit
antihaa
form
aggreg
shown
figur
electron
microscopi
although
rapid
practic
routin
test
antigen
complex
expens
howev
especi
use
test
detect
haa
gradient
sensit
directli
proport
number
time
well
refil
degre
specimen
concentr
dehydr
test
haa
antihaa
simultan
sensit
enough
detect
carrier
haa
excel
screen
blood
donor
excel
screen
blood
donor
autom
uniqu
detect
haaantibodi
complex
best
test
antihaa
use
routin
haatest
autom
complex
routin
use
purifi
concentr
haa
retain
morpholog
characterist
may
lose
antigen
activ
purif
procedur
tabl
electron
microscopi
also
valuabl
identifi
circul
antigenantibodi
complex
may
detect
immunolog
test
radioimmunoassay
immunolog
assay
use
purifi
haa
label
radioact
iodin
describ
recent
test
involv
incub
label
antigen
two
three
day
serum
test
antibodi
perform
chromatoelectrophoresi
separ
free
label
antigen
antibodybound
label
antigen
stain
locat
separ
peak
dri
paper
strip
count
automat
strip
scanner
assay
antibodi
take
approxim
six
day
detect
antibodi
radioimmunoassay
hemagglutin
assay
equal
sensit
hemagglutin
simpler
faster
detect
haa
radioimmunoassay
appear
sensit
complement
fixat
hemagglutin
complic
routin
use
haa
detect
complement
fixat
extract
liver
biopsi
specimen
patient
haaposit
hepat
howev
millman
cowork
describ
fluoresc
antibodi
technic
detect
haa
liver
cell
involv
flood
smear
minc
tissur
prepar
rabbit
antihaa
label
fluorescein
isothiocyan
fluoresc
granul
consid
specif
haa
observ
within
nuclei
almost
everi
liver
cell
four
patient
haaposit
hepat
patient
without
hepat
group
worker
describ
specif
haa
granul
spleen
bone
marrow
test
mesenteri
patient
haaposit
hepat
well
liver
addit
fifteen
patient
haa
blood
show
granul
liver
find
interpret
indic
fluoresc
test
sensit
agar
gel
immunodiffus
test
detect
haa
fluoresc
antibodi
technic
difficult
perform
blumberg
et
al
state
test
prove
use
find
alreadi
publish
support
addit
studi
confirm
laboratori
viru
cultur
anim
transmiss
subhuman
primat
especi
higher
scale
evolut
appear
anim
haa
propag
haa
well
antihaa
found
blood
chimpanze
orangutan
gibbon
monkey
tabl
v
although
number
preliminari
report
appear
past
adapt
viral
hepat
agent
chick
embryo
tissu
cultur
haa
yet
propag
tissu
cultur
usual
laboratori
anim
goal
attempt
develop
biolog
test
involv
tissu
cultur
infect
approach
sensit
human
suscept
infect
test
sensit
permit
detect
minimum
amount
viru
transmit
diseas
evalu
immun
respons
term
viru
neutral
tabl
ix
compar
variou
technic
measur
haa
antihaa
blood
reagent
sourc
antibodi
antigen
patient
given
repeat
transfus
blood
blood
product
best
sourc
high
titer
igg
precipit
complement
fixat
antibodi
onethird
sever
hemophilia
requir
frequent
treatment
plasma
cryoprecipit
fraction
antibodi
util
diagnost
purpos
best
antibodi
anamnest
hyperimmun
antibodi
reach
peak
titer
two
week
therapi
blood
blood
product
chanc
contain
haa
antibodi
especi
suitabl
complement
fixat
test
aris
decay
characterist
shown
figur
antiserum
precipitin
complement
fixat
properti
although
diffef
antiserum
may
better
one
type
oftestthan
human
immun
occur
less
frequent
countri
england
whidh
haa
carrier
less
preval
unit
state
less
half
patient
hemophilia
patient
whose
serum
contain
high
titer
antihaa
histori
hepat
excel
precipit
antibodi
haa
produc
anim
sensit
human
plasma
contain
haa
absorb
antiserum
normal
plasma
antiserum
produc
way
give
line
ident
human
antihaa
antiserum
suitabl
complement
fixat
procedur
absorpt
step
make
markedli
anticomplementari
haa
separ
plasma
doubl
isopycn
band
cesium
chlorid
follow
rate
zonal
centrifug
sucros
pure
enough
stimul
specif
complement
fixat
antihaa
antibodi
guinea
pig
high
qualiti
complement
fixat
antibodi
found
chimpanze
immun
purpos
chimpanze
blood
inadvert
contain
haa
similar
antiserum
produc
chimpanze
intent
immun
partial
purifi
haa
antiserum
chimpanze
specif
human
antibodi
haa
immun
higher
primat
could
provid
good
sourc
standard
high
titer
complement
fixat
antibodi
specif
reagent
line
ident
like
shown
figur
obtain
antigen
differ
sourc
fiftythre
differ
antiserum
antigen
test
whether
blood
patient
clinic
diagnos
serum
infecti
hepat
fresh
store
twenti
year
separ
purifi
suspens
particl
gave
line
ident
agar
gel
diffus
react
similarli
complement
fixat
haa
nonhuman
primat
respect
ident
haa
human
be
although
one
might
expect
structur
contain
haa
antigen
multispecif
yet
firm
evid
hepat
viru
produc
one
antigen
protein
small
virus
consist
multipl
unit
singl
polypeptid
sever
polypeptid
therefor
antigen
determin
haa
evid
major
antigen
determin
longincub
hepat
viru
would
surpris
antiserum
found
distinguish
antigen
subtyp
report
leven
blumberg
concern
antiserum
appear
recogn
second
hepat
associ
antigen
antiserum
form
earli
cours
immun
one
rabbit
human
plasma
contain
haa
disappear
immun
rabbit
spur
ouchterloni
doubl
diffus
consid
repres
line
nonident
known
haa
faint
photograph
reproduct
find
conceiv
could
reflect
differ
diffus
rate
rabbit
antibodi
specif
rather
antibodi
differ
specif
differ
haa
antigen
doubt
identifi
futur
exampl
zuckerman
et
al
found
particl
similar
structur
corona
viru
patient
chronic
activ
hepat
found
particl
serum
known
transmit
shortincub
longincub
hepat
also
find
new
antigen
stool
mani
patient
haaposit
hepat
suggest
agent
perhap
helper
virus
may
involv
hepat
addit
hepat
associ
antigen
document
system
nomenclatur
necessari
